These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 35880547)

  • 1. New and developing pharmacotherapies for hypertension.
    Höcht C; Allo MA; Polizio AH; Morettón MA; Carranza A; Chiappetta DA; Choi MR
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):647-666. PubMed ID: 35880547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newer Drugs to Reduce High Blood Pressure and Mitigate Hypertensive Target Organ Damage.
    Upadhya B; Kozak PM; Stacey RB; Vasan RS
    Curr Hypertens Rep; 2022 Jan; 24(1):1-20. PubMed ID: 35165832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sacubitril/valsartan in the treatment of middle-aged and elderly patients with hypertension: a systematic review and meta-analysis of randomized controlled trials.
    Wu HX; Liu KK; Li BN; Liu S; Jin JC
    Ann Palliat Med; 2022 May; 11(5):1811-1825. PubMed ID: 35672897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat.
    Rubattu S; Cotugno M; Forte M; Stanzione R; Bianchi F; Madonna M; Marchitti S; Volpe M
    J Hypertens; 2018 Sep; 36(9):1902-1914. PubMed ID: 29916993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the fixed-dose combination sacubitril/valsartan for the treatment of arterial hypertension.
    Wehland M; Simonsen U; Buus NH; Krüger M; Grimm D
    Expert Opin Pharmacother; 2020 Jul; 21(10):1133-1143. PubMed ID: 32133873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
    Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M
    J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities.
    Przezak A; Bielka W; Pawlik A
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-neprilysin inhibition confers renoprotection in rats with diabetes and hypertension by limiting podocyte injury.
    Uijl E; 't Hart DC; Roksnoer LCW; Groningen MCC; van Veghel R; Garrelds IM; de Vries R; van der Vlag J; Zietse R; Nijenhuis T; Joles JA; Hoorn EJ; Danser AHJ
    J Hypertens; 2020 Apr; 38(4):755-764. PubMed ID: 31790054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension.
    Li W; Gong M; Yu Q; Liu R; Chen K; Lv W; Yao F; Xu Z; Xu Y; Song W; Jiang Y
    J Clin Hypertens (Greenwich); 2022 Apr; 24(4):449-456. PubMed ID: 35253964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure.
    Reed JW
    Vasc Health Risk Manag; 2016; 12():393-405. PubMed ID: 27822054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Jackson AM; Jhund PS; Anand IS; Düngen HD; Lam CSP; Lefkowitz MP; Linssen G; Lund LH; Maggioni AP; Pfeffer MA; Rouleau JL; Saraiva JFK; Senni M; Vardeny O; Wijkman MO; Yilmaz MB; Saito Y; Zile MR; Solomon SD; McMurray JJV
    Eur Heart J; 2021 Sep; 42(36):3741-3752. PubMed ID: 34392331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study.
    Schmieder RE; Wagner F; Mayr M; Delles C; Ott C; Keicher C; Hrabak-Paar M; Heye T; Aichner S; Khder Y; Yates D; Albrecht D; Langenickel T; Freyhardt P; Janka R; Bremerich J
    Eur Heart J; 2017 Nov; 38(44):3308-3317. PubMed ID: 29029087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacubitril/valsartan instead of renin-angiotensin system inhibition alone: A step forward in resistant hypertension.
    Stavropoulos K; Imprialos KP; Doumas M
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):65-68. PubMed ID: 29237097
    [No Abstract]   [Full Text] [Related]  

  • 14. AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan.
    Zhao Y; Ma R; Yu X; Li N; Zhao X; Yu J
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):450-459. PubMed ID: 31023080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical case: early connection of valsartan/sacubitril in the treatment of hypertension].
    Lozhkina NG; Spiridonov AN
    Kardiologiia; 2022 May; 62(5):72-74. PubMed ID: 35692177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Firibastat: a Novel Treatment for Hypertension.
    Nesbitt SD
    Curr Hypertens Rep; 2021 Dec; 23(12):46. PubMed ID: 34950965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond.
    Kario K
    Curr Cardiol Rep; 2018 Jan; 20(1):5. PubMed ID: 29374807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose combination therapy in hypertension: pros.
    Taddei S
    High Blood Press Cardiovasc Prev; 2012 Jun; 19(2):55-7. PubMed ID: 22867090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncontrolled by olmesartan: A randomized, double-blind, 8-week study.
    Cheung DG; Aizenberg D; Gorbunov V; Hafeez K; Chen CW; Zhang J
    J Clin Hypertens (Greenwich); 2018 Jan; 20(1):150-158. PubMed ID: 29338113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.